Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial
Nature Medicine, Published online: 15 September 2026; doi:10.1038/s41591-026-04644-8 In the phase 2 RIO trial, there was delayed viral rebound and resistance to broadly neutralizing antibodies 3BNC117-LS and 10-1074-LS in adult males living with…
Read the full story at Nature Medicine ↗
ImpactNotable 38/100
Why it mattersRule-based estimate: no strong signals; trust 10/10.
RegionsGlobal
Published4 d ago (Tue, 15 Sep 2026 00:00:00 GMT)
RetrievedTue, 15 Sep 2026 10:01:55 GMT via rdf
ClassifiedTue, 15 Sep 2026 10:02:08 GMT by heuristic
AuthorMarcilio J. Fumagalli